Ekso Bionics Stock Price, News & Analysis

Ekso Bionics (NASDAQ: EKSO) has announced a 1-for-15 reverse stock split effective May 27, 2025. The split will reduce outstanding common stock from approximately 35,289,695 to 2,352,646 shares. The primary purpose is to raise the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for at least ten consecutive trading days.

The reverse split, approved by shareholders on May 16, 2025, will affect all issued shares, including adjustments to stock options, warrants, and restricted stock units. No fractional shares will be issued, with any fractional shares being rounded up. The company will maintain its "EKSO" trading symbol but will trade under a new CUSIP number 282644 400.

Ekso Bionics (NASDAQ: EKSO) has been accepted into the prestigious NVIDIA Connect program, marking a significant step in the company's AI development strategy. The exoskeleton technology leader plans to leverage NVIDIA's resources to develop the world's first foundation model for human motion in physical rehabilitation.

Through this selective program, Ekso Bionics will gain access to specialized training, priority engineering support, and exclusive NVIDIA GPU platforms and development kits. The company aims to integrate new AI capabilities across its Enterprise Health and Personal Health device portfolio. CEO Scott Davis emphasized that while their exoskeleton technology is already advanced, this collaboration represents just the beginning of their AI journey in rehabilitation technology.

Ekso Bionics (NASDAQ: EKSO) reported its Q1 2025 financial results, showing a revenue decline to $3.4 million from $3.8 million in Q1 2024. The company announced two strategic partnerships: naming National Seating & Mobility (NSM) as exclusive Ekso Indego Personal device distributor in the U.S. CRT industry, and Bionic Prosthetics & Orthotics Group as its first distributor in the orthotics and prosthetics sector. Gross margin improved to 53.5% from 51.9%. Net loss narrowed to $2.9 million ($0.12 per share) compared to $3.4 million ($0.20 per share) in Q1 2024. The company improved its operating cash burn by 43% and secured $3.8 million from warrant exercises, ending the quarter with $8.1 million in cash and restricted cash.

Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its Q1 2025 financial results announcement for May 5, 2025, after market close.

The company will host a conference call on the same day at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss:

• First quarter 2025 financial performance
• Recent business developments
• Company updates

Interested participants can join the conference call by dialing:

Domestic: 877-407-6184

International: 201-389-0877

The presentation will be broadcast live and archived on the company's investor relations website at www.eksobionics.com under the "Presentations & Events" section.

Ekso Bionics (Nasdaq: EKSO) has announced a non-exclusive distribution agreement with Bionic Prosthetics & Orthotics Group (Bionic P&O) for the Ekso Indego® Personal device, marking the company's first entry into the orthotics & prosthetics industry.

The Ekso Indego Personal is a wearable powered exoskeleton for individuals with spinal cord injuries (SCIs), featuring:

• Modular quick connect design for independent use
• Lightest commercial exoskeleton available
• Advanced gait mode enabling faster walking speeds
• Enhanced independence for users

This strategic alliance aims to leverage Bionic P&O's expertise in market dynamics, reimbursement landscape, and patient needs to effectively distribute the innovative device within the O&P community.

Ekso Bionics (NASDAQ: EKSO) reported its Q4 and full-year 2024 financial results, achieving record Q4 revenue of $5.1 million, up 5% year-over-year. Q4 gross margin improved by 400 basis points to 53%. The company recently named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor in the U.S.

For full-year 2024, revenue was $17.9 million, down 2% from 2023. Gross profit reached $9.5 million with a 53% margin. Net loss improved by 25% to $11.3 million ($0.56 per share) compared to $15.2 million in 2023. Operating expenses decreased across all categories, with cash usage improving to $9.8 million from $12.1 million in 2023. The company ended 2024 with $6.5 million in cash and restricted cash.

Ekso Bionics (Nasdaq: EKSO), a leader in exoskeleton technology for medical and industrial applications, has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss financial results and recent business developments. Investors can participate via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be available through a live broadcast and archive on the company's investor relations website.

Ekso Bionics Holdings (NASDAQ: EKSO) has named National Seating & Mobility (NSM) as the exclusive distributor of Ekso Indego® Personal device within the Complex Rehabilitation Technology (CRT) industry in the United States. The Ekso Indego Personal is a powered exoskeleton that enables individuals with spinal cord injuries to stand and walk independently.

The device features a unique modular quick connect design allowing users to operate it without assistance, and is the lightest commercial exoskeleton available. Users have demonstrated faster walking speeds with its advanced gait mode, enhancing their community independence.

NSM, a leading provider of CRT and mobility solutions, will leverage its expertise and insurance partnerships to expand access to the technology. The partnership aligns with Ekso Bionics' growth strategy and aims to broaden the availability of innovative mobility solutions.

Ekso Bionics (NASDAQ: EKSO) has announced preliminary Q4 2024 financial results, expecting record revenues between $5.0-$5.1 million, up from $4.8 million in Q4 2023. The company highlighted progress with initial CMS reimbursement for Ekso Indego Personal, expanding Medicare patient access.

Cash position as of December 31, 2024, stood at $6.5 million, down from $8.6 million year-over-year. Net cash used in operations for Q4 2024 was approximately $1.5 million, slightly improved from $1.6 million in Q4 2023. The company notes these are preliminary unaudited results subject to potential adjustments during the final review process.